Indian Pharma Market January 2016 Highlights :steady growth continues
1. January-16 marks the beginning of the last quarter for the Indian Companies and the 1st quarter for the MNCs. The first month began with a bit muted growth. In the previous month pharma market added Rs. 667 crore, as against Rs. 822 crore during January 2015
2. The average growth of the pharma market since April 2015 has been 13.2%. For the running quarter, growth has been 10.0%.
3. During April–Jan 2016, the market value is Rs. 82240 crore, as against Rs. 72696 crore during the same period last year.
4. For the previous month, the growth drivers were – 1.2% on account of volume growth, 5.1% due to price increase & 2.8% because of new introductions. Jan 2016 quarter saw a volume growth of 2.3%, as against 6.0% in Jan 2015 quarter. Overall growth for the quarter was 10.0%, as against 12.8% for the same period last year.
Major Highlights for Month of January 2016
December Month Highlights
1. The pharma market clocked Rs. 8014 crore during the previous month
2. 9.1% growth was registered in the previous month
Corporate
1. In the previous month, amongst the top 10, Mankind grew by 26.8%, Lupin by 13.4% & Macleods at 12.7%
2. 25 Corporates grew at a faster rate than the overall market growth
3. Amongst the top 50 Corporates, Bharat Serums had the highest growth at 34.8%, followed by Hetero at 29.0% & Mankind at 26.8%
4. 23 Corporates had a double digit growth, amongst the top 50
5. Amongst the 11-20 ranked Corporates, Alembic had the highest growth of 23.0%, followed by Aristo at 17.3% & Glenmark at 16.3%
6. Amongst the 21-30 ranked Corporates, FDC had the highest growth at 14.2%, followed by Cadila at 11.3% & Novartis at 10.0%
7. Amongst the 31-40 ranked Corporates, Bharat Serums grew at 34.8%, followed by Hetero at 29.0% and JBCPL at 13.5%
8. Amongst the 41-50 ranked Corporates, Troikaa had the highest growth at 21.5%, followed by Wallace at 16.6% & Systopic at 15.8%
9. Amongst the 51-60 ranked Corporates, Boehringer grew at 49.5%, followed by Corona at 32.4% & Centaur at 24.2%
10. Amongst the 61-70 ranked Corporates, RPG grew at 25.2% followed by Geno grew at 12.0% and East India at 11.8%
11. Amongst the 71-80 ranked Corporates, Samarth grew at 21.3% followed by Shreya at 20.2% & Walter Bushnell at 18.2%
12. Amongst the 81 -90 ranked Corporates, Galpha grew at 49.2%, followed by Veritaz grew at 40.5% followed by Dabur at 30.9%
13. Amongst the 91- 100 ranked Corporates, Ozone grew at 30.2%, followed by Serum Institute at 25.9% and Gland at 22.8%
14. 100th Biggest Corporate is Gland Pharma and 150th Biggest Corporate is Claris
15. MSD crossed the Rs. 1000 crore mark, Dey’s Medical, Ozone, Johnson & Johnson crossed the Rs. 100 crore mark, Medo Pharma & La Renon entered the Rs. 50 crore slab on MAT Basis
Indian V/s MNC
1. While Indian companies grew at 11.4%, MNCs growth was just 1.5%
2. Amongst the MNCs in top 50, Merck grew at 11.9% followed by Novartis at 10.0% and GSK at 6.1%
3. Under the Non-NLEM category, Indian companies grew at 12.4%, whereas MNCs grew at 1.1%
NLEM, Non NLEM & Non-Scheduled Para 19 market
1. The NLEM containing molecules segment grew at 5.3%, the non DPCO segment grew by 9.8% & Non-Sch. Para 19 segment at 6.4%, leading to overall growth of 9.1% in the previous month
2. NLEM & Non-NLEM category showed unit growth at 4.3% and 2.5% respectively. The Non-Sch Para 19 Market grew at 0.0% from units perspective
Therapy
1. 9 therapies had growth faster than the market
2. Respiratory therapy grew at 17.8%, Gastrointestinal at 11.7%, Pain & Analgesics at 8.1% whereas Anti-infectives grew at 11.9%
3. In chronic business, Anti-diabetic at 9.4% and Cardiac grew at 7.3%
4. Derma grew by 9.0% & Urology at 4.1%.
5. Anti-Malarial de-grew at 20.1%
Regional Dynamics
1. 13 regions grew faster than the market growth
2. Odisha had the highest growth at 20.0%%, followed by Jharkhand at 19.4% & Bihar at 19.3%
3. Tamil Nadu had a very low growth at 1.7% , while 2 regions had negative growth
Molecules
1. Amoxycillin + Clavulanic Acid grew at 16.4% & Glimepiride + Metformin grew at 8.8%
2. The Paracetamol grew at 28.4%, Atorvastatin 1.3%, Probiotic Microbes at 28.2%, Cefixime 7.1%, Pantoprazole 14.9%, Montelukast + Levocetrizine at 15.3%, Glimepiride + Metformin + Pioglitazone at 9.8%, Vitamin-D at 19.4%, Hydroquinone + Mometasone + Tretinoin at -9.0%, Voglibose + Metformin + Glimepiride at 30.7%, Rosuvastatin at 12.6%, Protein Supplements at 11.4%, Azithromycin at 17.1%, Calcium Carbonate + Vit D3 market at 0.8%, Paracetamol + Phenylephrine + Chlorpheniramine at 15.2%, Meropenem at 45.1%, Montelukast + Fexofenadine at 36.9%
3. 50th ranked molecule is Sildenafil, while 100th ranked is Cefalexin
Brands
1. Mixtard lead the pack with Rs. 31 crore, followed by Corex at Rs. 29 crore, Glycomet GP & Augmentin at Rs. 28 crore in the previous month
2. Few brands which gained ranks include Aciloc RD (+94), Electral Powder (+68), Unwanted Kit (+64), Rotarix (+47), Meronem (+43), Duolin (+39), Betnesol (+30), Rabipur (+28), Vertin (+27), Jalra M (+26), Ultracet, Betnovate N (+23), Deriphyllin (+21), Sapsmoproxyvon Plus (+20), Monocef –O (+18), Trajenta (+17)< Budecort (+16), Betnovate C , Dolo (+15), Levipil (+14), Voveran, Pamderm Plus, Telma, Rosuvas, Ascoril Plus (+13), Pan, Calpol, Thyronorm, Januvia, Azithral (+12), Janumet (+11), Telma H, Pantocid D SR (+10), Taxim-O, Moxikind CV, Gluconorm-G (+9), GalvusMet, Susten, Rantac, Pantop (+8), Clavam, Sinarest (+4) amongst top 100 Brands over January–2015
3. Mero (+182), Finecef (+151), Lobate GM (+107), Zerodol SP, Pipzo (+88), Enterogermina (+87), Cilacar (+76), P (+75), Brilinta, Moxclav (+68), Grilinctus (+41), Bevon (+25) are few brands which gained ranks in 101-200 segment
4. Among the top 300 brands,brands that moved up fastest were Ocid, Grafeel, Similac, Candiforce, Reditux, Anafortan, Mero
5. 300th ranked brand is Reditux from DRL
New Launches in IPM
1. 239 Brands & 401 SKUs were launched in the previous month
2. Top new brands were Ledviclear, Sofab LP, Hepcinat LP
3. 3 new brands were launched in Sofosbuvir + Ledipasavir category
4. In the VMS category, new brands were Folyblend (Akesiss), Pforu (Galpha), Macgesia (Macleods)
5. In Anti-diabetic, the new brands were Kmet Duo (Blue Cross), Glurest M (Alde Medi Impex), Satrvog GM ( Merck)
6. In Respiratory, new brands were Solitair (Blue Cross), Monokast FX, Monokast (TTK), Ebmont FX3 (MMC)
Biggest new launch by a MNC is Ledviclear
Comments
Post a Comment